Destruction of insulin-producing pancreatic b-cells by local autoimmune inflammation is a hallmark of type 1 diabetes. Histochemical analysis of pancreases from non-obese diabetic mice indicated activation of the transcription factor JunB/AP-1 (activator protein-1) after autoimmune infiltration of the islets. In vitro studies demonstrated that the cytokines tumor necrosis factor (TNF)-a and interferon (IFN)-c induce JunB expression as a protective mechanism against apoptosis in both human and rodent b-cells. The gene network affected was studied by microarray analysis showing that JunB regulates nearly 20% of the cytokine-modified b-cell genes, including the transcription factor ATF3. Direct transcriptional induction of ATF3 by JunB is a key event for b-cell survival after TNF-a þ IFN-c treatment. Moreover, pharmacological upregulation of JunB/ATF3 via increased cAMP protected rodent primary b-cells and human islet cells against pro-inflammatory mediators. These results were confirmed in genetically modified islets derived from Ubi-JunB transgenic mice. Our findings identify ATF3 as a novel downstream target of JunB in the survival mechanism of b-cells under inflammatory stress.
Introduction
Type 1 diabetes (T1D) affects the quality of life of millions of individuals worldwide. In the United States, the prevalence of T1D is around 2 million people and is increasing at an alarming 3% annual rate (Borchers et al., 2010) . The disease generally develops in childhood or youth and is characterized by progressive loss of pancreatic b-cells due to an autoimmune assault (Eizirik et al., 2009 ). The immune system, for reasons that remain to be clarified, selectively targets b-cells that die mostly by apoptosis (Eizirik and Mandrup-Poulsen, 2001 ). Loss of b-cells renders the patient insulindependent for life. Pro-inflammatory cytokines have a major role in the pathogenesis of T1D. Tumor necrosis factor (TNF)-a or interleukin (IL)-1b (secreted by infiltrating macrophages) combined with interferon (IFN)-g (secreted by T-cells) trigger b-cell apoptosis contributing to the build-up of insulitis (Eizirik and Mandrup-Poulsen, 2001; Eizirik et al., 2009) . These cytokine combinations activate complex downstream transduction signals that include the transcription factors STAT1, NF-kB and AP-1 (activator protein-1) (Eizirik et al., 2009) . The final outcome is b-cell apoptosis induced by the mitochondrial pathway of cell death .
A variety of components of the JUN, FOS and ATF families can form active dimeric AP-1 molecules (Shaulian and Karin, 2002) . The JUN proteins form homo or heterodimers with FOS and ATF proteins, which modulate gene expression. The role of the AP-1 transcription factor as a cell cycle modulator has been intensely studied in cancer models (Eferl and Wagner, 2003) . Less is known, however, on the role of AP-1 in differentiated cells. It was recently shown that inactivation of the JUN components JunB and c-Jun in epidermal cells contribute to the development of autoimmune diseases like psoriasis and arthritis (Zenz et al., 2005) . In addition, mice lacking epidermal JunB develop skin inflammation and systemic lupus erythematosus (Meixner et al., 2008; Pflegerl et al., 2009) . The role of AP-1 in the pathogenesis of autoimmune T1D is unknown. Our previous in vitro studies indicate that cytokine-induced AP-1 can be anti-or pro-apoptotic in rodent b-cells depending on the AP-1 component, the context and the time of activation (Gurzov et al., 2008 Colli et al., 2010) . To better define the role of AP-1 in diabetes, we have performed an extensive analysis of the expression and role of different JUN members in b-cell apoptosis using human islets, rodent b-cells, non-obese diabetic (NOD) and transgenic Ubi-JunB mice. Knockdown of JunB and subsequent microarray analysis of cytokine-treated b-cells identified ATF3 as a novel and key JunB-regulated gene involved in b-cell protective mechanisms against inflammation.
Results
JunB and c-Jun are activated after TNF-a þ IFN-g exposure of b-cells in vitro and in immune-infiltrated NOD islets in vivo The pro-inflammatory cytokine TNF-a combined with IFN-g-induced JunB mRNA expression in six different preparations of human islets isolated from non-diabetic organ donors (Figure 1a ). Cytokine-induced JunB overexpression was confirmed at protein level in whole human and mouse islets, in autofluorescence-activated cell sorting-purified primary rat b-cells and in the insulin-producing INS-1E cell line (Figure 1b and Supplementary Figure S1A) . The JUN component c-Jun was also activated in b-cells through phosphorylation after TNF-a þ IFN-g exposure, whereas JunD was not affected (Figure 1b ). Adenovirus AdIkB (SA)2 , expressing the IkB 'super-repressor' of NF-kB, prevented TNF-a þ IFN-g-induced JunB expression (Figure 1c and Supplementary Figure S1B ), indicating that TNF-a þ IFN-g-mediated JunB activation in b-cells is regulated by NF-kB. To examine whether c-Jun phosphorylation depends on c-Jun N-terminal kinase (JNK) 1/2, we exposed INS-1E cells to TNF-a þ IFN-g with or without a previously validated JNK inhibitor (Gurzov et al., 2008) . Reduced cytokine-mediated JNK activation decreased c-Jun phosphorylation (Figure 1d ). The expression of JunB and c-Jun was next studied in pre-diabetic NOD mice, an in vivo model of autoimmune diabetes. Both proteins were induced in the pancreatic islets after insulitis development ( Figure 1e and Supplementary Figure S2A JunB has a protective role against TNF-a þ IFN-ginduced b-cell death Two different siRNAs (small interfering RNAs) against JunB or c-Jun were used to silence these proteins, achieving 460% silencing as compared with an inactive control siRNA in INS-1E cells (Figure 2a) . JunB or c-Jun knockdown increased TNF-a þ IFN-g-induced apoptosis at 16 h in INS-1E cells (Figures 2b and c) . This effect was also observed after JunB but not c-Jun knockdown in primary rat b-cells (Figure 2d) . Interestingly, c-Jun silencing protected b-cells against IL-1b þ IFN-g (Supplementary Figure S3A) , while knockdown of JunB increased apoptosis induced by this cytokine combination (Supplementary Figure S3B) , as observed with TNF-a þ IFN-g. JunB regulates iNOS, Chop and DP5 expression in the context of IL-1b þ IFN-g-induced b-cell apoptosis (Gurzov et al., 2008 ). Knockdown of JunB, however, did not affect the induction of these proteins after TNFa þ IFN-g exposure, indicating a different mechanism of action (Supplementary Figures S4A, B, C and D) . Promoter analysis demonstrated that the CRE or ATF/ CRE binding sites in the Chop and DP5 promoter previously shown to mediate the stimulatory effect of IL-1b þ IFN-g (Gurzov et al., 2008 are not required for TNF-a þ IFN-g-mediated gene induction (Supplementary Figures S4E and F) . Furthermore, the upregulation of these genes is lower in b-cell exposed to TNF-a þ IFN-g as compared with IL-1b þ IFN-g (Supplementary Figure S5) . Together, these results suggest that JunB has a major role in b-cell protection and acts thorough multiple and context-dependent mechanisms.
ATF3 induction is mediated by JunB in b-cells exposed to cytokines The gene networks modulated by JunB in b-cells after TNF-a þ IFN-g exposure was studied by expression profiling. INS-1E cells transfected with siRNA control or JunB 2 were treated with TNF-a þ IFN-g for 6 or 14 h, and the expression of 21 569 probe sets corresponding to 10 874 annotated genes was analyzed (selection criteria are detailed in Supplementary Information, Material and Methods). JunB knockdown affected the expression of 20-25% of the genes in TNF-a þ IFN-g-treated cells. Supplementary Table S1 shows selected genes with a putative role in b-cell function and death in the context of T1D. It was recently demonstrated that c-Jun directly inhibits MafA expression in in vivo models of diabetes (Matsuoka et al., 2010) . Here we observed that JunB silencing downregulates MafA and Ins2, two genes involved in the development and maintenance of the b-cell differentiated phenotype, a finding confirmed by real time RT-PCR in independent samples (Supplementary Figure S6A) . These data indicate an opposite role of JunB and c-Jun in MafA modulation. JunB knockdown, however, did not affect insulin content or secretion in INS-1E cells (Supplementary Figure S6B) . Aco2, p21 and Bcl-XL regulation by JunB was also unraveled by Figure S9B ). We next analyzed the nucleotide sequence responsible for TNF-a þ IFN-g-induced ATF3 transcription using ATF3 promoter reporter constructs (Tamura et al., 2005) . The promoter sequence À1850 to À84 was essential for cytokine-induced ATF3 activation ( Figure 3e ). Studies in fibroblasts have shown that this region harbors a conserved ATF/CRE motif at À92 to À85 where c-Jun can bind after serum stimulation (Tamura et al., 2005) . Mutations in the ATF/CRE site abolished TNF-a þ IFN-g-induced ATF3 promoter activation in INS-1E cells (Figure 3e ), indicating that this ATF/CRE motif is crucial for ATF3 gene transcription. Chromatin immunoprecipitation analysis confirmed JunB binding to this region (Figure 3f ). We next examined whether modulation of JunB-mediated Figure  S9C) . Importantly, silencing of ATF3 (Figure 4e ) also increased cell death induced by TNF-a þ IFN-g in dispersed human islets (Figure 4f ). ATF3 inactivation decreased Bcl-XL expression and increased TNFa þ IFN-g-induced cleavage caspase-9 and -3 without modifying the expression of Bax, Bak or Bcl-2 (Supplementary Figures S10A and B) . Our results indicate that JunB-mediated ATF3 upregulation is part of the b-cell defense mechanisms against apoptosis triggered following exposure to the pro-inflammatory cytokines TNF-a þ IFN-g or IL-1b þ IFN-g.
Pharmacologic or genetic upregulation of the JunB/ATF3 pathway protects b-cells against TNF-a þ IFN-g To pharmacologically upregulate JunB, we exposed b-cells to forskolin, which activates the cyclic AMP/ protein kinase A (cAMP/PKA) pathway, leading to JunB overexpression (Kobierski et al., 1991; PerezAlbuerne et al., 1993; Schmidt et al., 2007; Cunha et al., 2009) . Forskolin increased JunB and ATF3 proteins in b-cells (Figures 5a and b) , and inactivation of PKA prevented this effect (Supplementary Figure S11A) . Consistent with these findings, JunB inactivation decreased forskolin-induced ATF3 expression (Supplementary Figure S11B ). Furthermore, forskolin prevented caspases activation and protected INS-1E cells against TNF-a þ IFN-g-induced apoptosis; this effect was lost after siRNA-mediated JunB or ATF3 knockdown (Figures 5c, d and e) . The protective action of forskolin was also observed against TNF-a þ IFN-ginduced apoptosis in dispersed human islets (Figure 5f ).
The role of JunB was further addressed by using the Ubi-JunB mouse model (Schorpp et al., 1996) . JunB transgenic mice broadly overexpressing JunB have no overt phenotype (Schorpp et al., 1996) , and intraperitoneal glucose tolerance test showed a well-preserved glucose tolerance when compared with wild-type littermates (Supplementary Figure S12A) . Moreover, insulin secretion was similar in Ubi-JunB and wild-type control mice (Supplementary Figure S12B) . Histochemical analysis of the mice pancreases showed increased JunB nuclear expression in islets from Ubi-JunB mice (Figure 6a ). Western blot studies of isolated islets from Ubi-JunB or control mice confirmed JunB upregulation in Ubi-JunB islets (Figure 6b ). In line with our previous observations, increased expression of JunB upregulated ATF3 protein levels (Figure 6b ). Importantly, islets from Ubi-JunB mice were protected against TNFa þ IFN-g-induced apoptosis (Figure 6c) , and displayed reduced cytokine-induced activation of caspase-3 as detected by western blot (Figure 6d ). Taken together, these data indicate that pharmacological or genetic overexpression of JunB protects b-cells against pro-inflammatory cytokine induction of apoptosis at least in part via ATF3 upregulation.
Discussion
Dying b-cells act as a 'danger signal' in the context of islet inflammation contributing to the maturation of dendritic cells, activation of T-cells and amplification of the autoimmune reaction in early T1D (Eizirik et al., 2009) . We presently show by the use of array analysis and different in vivo and in vitro rodent models that activation of the AP-1 protein JunB (but not c-Jun) is critical for b-cell resistance against cytokine-induced apoptosis. The protective effect of JunB is mediated at least in part via activation of the downstream transcription factor ATF3. These findings were confirmed in human islets from different donors, suggesting relevance for human disease.
TNF-a when combined with IFN-g induces b-cell demise mainly via apoptosis (Eizirik and MandrupPoulsen, 2001; Eizirik et al., 2009 ). This cytokine combination leads to an early activation of the transcription factor NF-kB and the JNK kinase, inducing JunB overexpression and c-Jun phosphorylation, respectively. JunB modulation by NF-kB was previously observed in b-cells and other cell types (Schmidt et al., 2007; Gurzov et al., 2008) . JunB has a protective role against different apoptotic stimuli in b-cells (present data), while the action of c-Jun is unclear and seems to be less relevant for primary b-cells than for clonal INS-1E cells. The identity of pro-inflammatory cytokines may vary in the vicinity of the b-cells leading to alternative pathways of cell death (Eizirik et al., 2009) . JunB inactivation increased apoptosis induced by different cytokine combinations (that is, IL-1b þ IFN-g and TNF-a þ IFN-g), suggesting a broader and fundamental role of this so-called oncogene on the survival of highly differentiated b-cells during inflammation. In the context of IL-1b þ IFN-g, JunB acts by downregulating the expression of the pro-apoptotic genes iNOS, Chop and DP5 (Gurzov et al., 2008) . On the other hand, these proteins are only modestly induced by TNF-a þ IFN-g and are not modulated by the AP-1 responsive element present in their promoters. In spite of this, the global gene expression examined by array analysis unravels that JunB regulates nearly 25% of the TNF-a þ IFN-g-modified genes, including key genes such as MafA, p21, Aco2, Bcl-XL and ATF3.
Of particular interest among the JunB-modified genes in b-cells was the basic leucine zipper (b-Zip) type transcription factor ATF3. This protein is maintained at low levels in quiescent cells and activated by different stress signals, allowing modulation of gene networks that vary according to the cell type (Thompson et al., 2009) . ATF3 is induced in islets from pre-diabetic NOD mice, indicating that the in vitro observed phenomenon is also present in an in vivo model of autoimmuneinduced diabetes. Regulation of ATF3 gene expression can involve several transcription factors including cMyc, c-Jun, ATF2, ATF4, Nrf2 and NFATC1 (Jiang et al., 2004; Tamura et al., 2005; Kim et al., 2010; Wu et al., 2010) . Analysis of the ATF3 promoter demonstrated that its induction by pro-inflammatory cytokines is JunB dependent in b-cells and mediated by binding of JunB to an ATF/CRE responsive element. These findings provide a novel mechanistic regulation of the ATF3 gene by JunB in the context of inflammation. It has been reported that ATF3 knockout islets are resistant to pro-inflammatory cytokines (Zmuda et al., 2010b) . On the other hand, subsequent data from the same group suggested that b-cell function is inhibited in ATF3-deficient mouse islets (Zmuda et al., 2010a) . Our results are in line with the later study, ATF3 knockdown increases TNF-a þ IFN-g-induced apoptosis in rodent b-cells and dispersed human islets, indicating an antiapoptotic action of this protein. The discrepancy between our data and results obtained in mouse ATF3 knockout cells (Zmuda et al., 2010b) may be due to an adaptation response of the full systemic knockout model, which is not present when ATF3 is silenced in adult rodent or human b-cells. Here we observed that ATF3 silencing decreases expression of the pro-survival protein Bcl-XL, thus sensitizing b-cells to apoptosis induction by pro-inflammatory cytokines as previously shown (Carrington et al., 2009; Gurzov et al., 2010) . Consistent with this, Bcl-XL modulation by the AP-1 transcription factor was recently observed in other cell types (Salameh et al., 2010) . As a whole, these findings indicate that ATF3 has a central role for the antiapoptotic action of JunB.
Most of the experiments described above were based on inactivation of JunB or ATF3 by RNA interference technology. JunB overexpression in pancreatic islets from Ubi-JunB mice upregulates ATF3 and protects these islets against TNF-a þ IFN-g, as shown by caspase-3 cleavage and Hoechst 33342/propidium iodide Following 48-h TNF-a þ IFN-g treatment, Ubi-JunB and wild-type islets were harvested and cell lysates were subjected to western blot using anti-JunB and anti-ATF3 antibodies. (c) Islets from Ubi-JunB or wild-type mice were exposed to the cytokine combination TNF-a þ IFN-g for 48 h. The viability of islet cell preparations was assessed by Hoechst 33342/propidium iodide. Cell death was counted in at least 24 islets derived from 4 mice per condition. ***Po0.001. (d) Western blot for ATF3 and cleaved caspase-3 of isolated islets after 48 h of treatment with TNF-a þ IFN-g. staining, in a mirror situation to the observations made in JunB-inactivated b-cells. The JunB protein can also be pharmacologically modulated by cAMP generators (Kobierski et al., 1991; Cunha et al., 2009) , agents that are presently been tested for the early treatment of T1D (Bosi, 2010) . We observed that the cAMP generator forskolin induces JunB expression, upregulates ATF3 and decreases cleavage of caspases-9 and -3 by TNFa þ IFN-g in both rodent b-cells and dispersed human islets. Importantly, knockdown of ATF3 abrogates the beneficial effects of forskolin-induced JunB upregulation, confirming the central role for ATF3 in JunBmediated protection against cytokine-induced b-cell death. These data provide a molecular rationale on the use of cAMP generators and identify the JunB/ATF3 pathway as a potential therapeutic target for b-cell protection in early T1D.
In conclusion, our observations indicate that JunB, usually viewed as a cell cycle modulator in cancer, has a much broader spectrum of effects in highly differentiated b-cells. This AP-1 component affects expression of hundreds of genes modified by cytokines, and has a key pro-survival role in pancreatic b-cells under inflammatory stress.
Materials and methods

Cell culture and treatments
Human islets were isolated in Pisa (Italy) from non-diabetic organ donors, with the approval of the local Ethical Committee. The islets were isolated by enzymatic digestion and density gradient purification (Lupi et al., 2002) and cultured in M199 medium containing 5.5 mM glucose. Donor age was 52 ± 10 years, and the preparations contained 47 ± 7% b-cells (n ¼ 6), as evaluated by immune staining for insulin (methods as in Cunha et al., 2008) . Primary rodent islets were isolated from adult Wistar rats (Charles River Laboratories Belgium, Brussels, Belgium), from Ubi-JunB transgenic mice (Schorpp et al., 1996) or wild-type littermates (12-20-weekold) . Pre-diabetic NOD or control BALB/c mice were maintained under semibarrier conditions at the animal facility of KU Leuven (Proefdierencentrum, Leuven, Belgium). Animals were bred and used in accordance with the guidelines of the Belgian Regulations for Animal Welfare. All experimental protocols used were approved by the Ethical Committee for Animal Experiments of the ULB or KU Leuven. Primary rat b-cell isolation and culture were carried out as previously described (Pipeleers et al., 1985; Moore et al., 2009) . Islet isolation was achieved by collagenase digestion and hand picking, purified primary rat b-cells (490%) were obtained after islet dispersion and autofluorescence-activated cell sorting sorting (FACSAria, BD Bioscience, San Jose, CA, USA). Sorted cells were plated on poly-lysine-coated dishes and pre-cultured in Ham's F-10 (Invitrogen, Paisley, UK) medium for 48 h before further experimental procedures. Mouse islet isolation was performed as previously described (Maida et al., 2008) . The insulin-producing INS-1E cell line (a kind gift from Professor C Wollheim, Centre Me´dical Universitaire, Geneva, Switzerland) was cultured in RPMI-1640 medium (Invitrogen) supplemented with 5% fetal calf serum, 0.1 mM sodium pyruvate, 1 mM Hepes and 0.5 mM 2-mercaptoethanol (Invitrogen) (Kutlu et al., 2003) . Recombinant rat (100 U/ml for INS-1E cells and 500 U/ml for primary rat b-cell), mouse (500 U/ml) or human (500 U/ml) IFN-g (R&D Systems, Abingdon, UK), recombinant murine TNF-a (1000 U/ml, Innogenetics, Ghent, Belgium), human recombinant IL-1b (50 U/ml for mouse islets and 10 U/ml for INS-1E cells, a kind gift from Dr CW Reinolds, National Cancer Institute, Bethesda, MD, USA), SP600125 (10 mM, Sigma, Steinheim, Germany), H89 inhibitor (15 mM, Sigma) and forskolin (20 mM, Sigma) were used. Cytokine concentrations were selected based on our previous time course and doseresponse studies (Eizirik and Mandrup-Poulsen, 2001; Kutlu et al., 2003) .
Adenovirus infection
After 48 h, pre-cultured cells were infected either with AdLUC (control luciferase expressing virus) or AdIkB (SA)2 (encoding a previously described NF-kB super-repressor protein (Heimberg et al., 2001) ). INS-1E cells were infected for 2 h at 37 1C with a multiplicity of infection of 10 for AdIkB (SA)2 or AdLUC.
Immunohistochemistry
Mouse pancreases were fixed in 4% formalin solution at 4 1C and embedded in paraffin. Immunohistochemistry was performed by an indirect immunoperoxidase method using antibodies for JunB and p-c-Jun (Cell Signaling, Danvers, MA, USA), or ATF3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Real time RT-PCR and western blot mRNA expression was determined by real time RT-PCR using SYBR Green fluorescence on a LightCycler instrument (Roche, Manheim, Germany). Expression of the gene of interest was divided by the house-keeping gene glyceraldehyde-3-phosphate dehydrogenase and expressed as fold induction compared with control. Primer sequences are provided in Supplementary Table S2 .
Equal amounts of proteins were resolved by 10% SDS-PAGE. Immunoblot analysis was performed according to standard protocols. The list of antibodies used is shown in Supplementary Table S3. All blots shown are representative for 2-4 independent experiments. siRNA treatment Cells were transfected overnight with 30 nM of specific siRNAs (Dharmacon, Chicago, IL, USA; Santa Cruz Biotechnology; or Invitrogen) or with an inactive control siRNA (Qiagen, Venlo, Netherlands) using DharmaFECT lipid reagent (Dharmacon) or Lipofectamine RNAiMAX transfection reagent (Invitrogen), and Opti-mem (Invitrogen). We have previously shown that the inactive control siRNA neither affects insulin release (Allagnat et al., 2011) nor gene expression . A target inhibition of 50-90% was obtained for all active siRNAs, similar to our previous studies (Cunha et al., 2008; Gurzov et al., 2009; Moore et al., 2009 Moore et al., , 2011 . The list of siRNAs used is shown in Supplementary  Table S4 . After overnight incubation, transfection medium was replaced by regular culture medium and cells were allowed to recover for a period of 36-48 h before further exposure to cytokines.
Cell viability
The percentage of cell death was determined in at least 600 cells per experimental condition by inverted fluorescence microscopy after staining with the DNA dyes Hoechst 33342 (10 mg/ml) and propidium iodide (5 mg/ml) ( Viability was evaluated by at least two observers, one of whom was unaware of sample identity. Apoptosis was confirmed by alternative methods (caspase-3 and -9 activation) as previously suggested (Galluzzi et al., 2009) .
ATF3 reporter assay
Previously described ATF3 promoter constructs driving the luciferase reporter gene were used (Tamura et al., 2005) . INS-1E cells were transfected for 6 h using lipofectamine (Invitrogen) with 250 ng of different luciferase reporter constructs and the pRL-CMV plasmid (50 ng), with Renilla luciferase used as internal control for transfection efficiency. At 24 h after transfection, the cells were exposed to TNF-a þ IFN-g for subsequent 24 h. Luciferase activities of cell lysates were then determined and represented as Firefly/Renilla (relative luciferase activity).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed as described (Kouskouti and Talianidis, 2005) . Extracts were pre-cleared by 1 h incubation with protein A/Herring sperm DNA at 4 1C. Samples were incubated overnight at 4 1C with anti-JunB antibody (Santa Cruz Biotechnology, 1:150) or preimmune goat serum as negative control. Immunocomplexes were conjugated with protein A/Herring sperm DNA and washed. Samples were then eluted, proteinase K treated and incubated overnight at 65 1C in high-salt solution to reverse the crosslink reaction. DNA fragments were analyzed by standard PCR, and input DNA was analyzed simultaneously for normalization. PCR was performed with the following primer pair for the ATF/CRE site À120 to þ 30 of the ATF3 promoter: 5 0 -GGCCAGTTCTCCCTGGAAGC-3 0 and 5 0 -AAGCACCTGGCACCGCGCGT-3 0 .
Statistical analysis
Data are means ± s.e.m. of 3-6 independent experiments. Comparisons between groups are made by paired t-test or by ANOVA followed by t-test with the Bonferroni correction.
